Logo image of CVKD

CADRENAL THERAPEUTICS INC (CVKD) Stock Fundamental Analysis

NASDAQ:CVKD - Nasdaq - US1276362076 - Common Stock - Currency: USD

19.89  +0.66 (+3.46%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CVKD. CVKD was compared to 193 industry peers in the Pharmaceuticals industry. CVKD has a great financial health rating, but its profitability evaluates not so good. CVKD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CVKD has reported negative net income.
CVKD Yearly Net Income VS EBIT VS OCF VS FCFCVKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

CVKD's Return On Assets of -153.14% is on the low side compared to the rest of the industry. CVKD is outperformed by 85.95% of its industry peers.
With a Return On Equity value of -209.33%, CVKD is not doing good in the industry: 71.89% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -153.14%
ROE -209.33%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CVKD Yearly ROA, ROE, ROICCVKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 200 -200 400 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CVKD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVKD Yearly Profit, Operating, Gross MarginsCVKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

CVKD has less shares outstanding than it did 1 year ago.
There is no outstanding debt for CVKD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CVKD Yearly Shares OutstandingCVKD Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2M 4M 6M 8M
CVKD Yearly Total Debt VS Total AssetsCVKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2M 4M 6M 8M

2.2 Solvency

An Altman-Z score of 5.85 indicates that CVKD is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.85, CVKD belongs to the best of the industry, outperforming 82.16% of the companies in the same industry.
There is no outstanding debt for CVKD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.85
ROIC/WACCN/A
WACCN/A
CVKD Yearly LT Debt VS Equity VS FCFCVKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 0 2M -2M 4M -4M 6M

2.3 Liquidity

A Current Ratio of 3.72 indicates that CVKD has no problem at all paying its short term obligations.
CVKD has a Current ratio (3.72) which is in line with its industry peers.
A Quick Ratio of 3.72 indicates that CVKD has no problem at all paying its short term obligations.
CVKD has a Quick ratio (3.72) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.72
Quick Ratio 3.72
CVKD Yearly Current Assets VS Current LiabilitesCVKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CVKD have decreased strongly by -993.02% in the last year.
EPS 1Y (TTM)-993.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CVKD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.07% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.36%
EPS Next 2Y25.69%
EPS Next 3Y19.6%
EPS Next 5Y12.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CVKD Yearly Revenue VS EstimatesCVKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 20M 40M 60M 80M 100M
CVKD Yearly EPS VS EstimatesCVKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CVKD. In the last year negative earnings were reported.
Also next year CVKD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVKD Price Earnings VS Forward Price EarningsCVKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CVKD Per share dataCVKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as CVKD's earnings are expected to grow with 19.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.69%
EPS Next 3Y19.6%

More info and screens

0

5. Dividend

5.1 Amount

CVKD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CADRENAL THERAPEUTICS INC

NASDAQ:CVKD (2/21/2025, 8:11:24 PM)

19.89

+0.66 (+3.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners5.53%
Inst Owner Change47800%
Ins Owners4.51%
Ins Owner Change0%
Market Cap35.40M
Analysts82.5
Price Target36.38 (82.91%)
Short Float %2.38%
Short Ratio0.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-56.53%
Min EPS beat(2)-73.01%
Max EPS beat(2)-40.06%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.87
P/tB 8.87
EV/EBITDA N/A
EPS(TTM)-9.29
EYN/A
EPS(NY)-3.89
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS2.24
TBVpS2.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -153.14%
ROE -209.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.72
Quick Ratio 3.72
Altman-Z 5.85
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-993.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y16.36%
EPS Next 2Y25.69%
EPS Next 3Y19.6%
EPS Next 5Y12.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-182.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.9%
EBIT Next 3Y-22.64%
EBIT Next 5Y-26.84%
FCF growth 1Y-194.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-194.19%
OCF growth 3YN/A
OCF growth 5YN/A